CT上单肺叶肺炎型浸润性黏液腺癌的预后:将其定为临床T3期是否合理?
本研究比较了局限于单肺叶的肺炎型浸润性黏液腺癌(pIMA)与无病理淋巴结转移的临床T2、T3、T4期肺癌根治术后的生存,并分析pIMA预后因素。pIMA的5年无复发生存率与临床T4期NSCLC相当,且显著差于临床T3期;CT上出现独立结节与pIMA较差的RFS和OS相关。
要点
- pIMA的5年RFS为33.1%,与临床T4期NSCLC相当,显著差于临床T3期(p=0.012)。
- pIMA的5年OS为56.0%,与临床T3或T4期NSCLC的OS差异均无统计学意义(p=0.11和p=0.37)。
- pIMA患者CT上出现独立结节与较差的RFS和OS显著相关(校正HR 4.53,95%CI 1.59-12.89)。
核心结论
- pIMA的RFS与临床T4期肺癌相当,CT上的独立结节与pIMA患者较差的RFS和OS相关。
研究设计与样本
- 两所三级医院回顾性识别2010年1月至2017年12月间CT示局限于单肺叶且接受根治性手术的pIMA患者41例(男15例,平均年龄66.0±9.9岁);参考组为同一参与机构内无病理淋巴结转移且接受根治性手术的非小细胞肺癌患者313例(男222例,66.3±9.4岁)。采用Kaplan-Meier法计算RFS和OS,Cox比例风险回归分析pIMA生存相关因素。
关键影像表现/征象
- pIMA在CT上表现为局限于单肺叶的肺炎型病变。
- pIMA患者CT上可见独立结节,该征象与较差的RFS和OS相关。
诊断标准与关键数值
- pIMA患者5年RFS为33.1%,5年OS为56.0%。
- 参考组临床T2期NSCLC的5年RFS为74.3%、OS为91%;临床T3期5年RFS为64.3%、OS为71.8%;临床T4期5年RFS为46.9%、OS为49.5%。
- pIMA与临床T4期NSCLC的RFS相当,显著差于临床T3期(p=0.012);pIMA与临床T3期和T4期NSCLC的OS差异均无统计学意义(p=0.11和p=0.37)。
- pIMA患者中,独立结节与较差RFS相关:未校正HR 4.66(95%CI 1.95-11.11),p<0.001;与较差OS相关:校正HR 4.53(95%CI 1.59-12.89),p=0.005。
临床应用与阅片要点
- 阅读pIMA患者CT时,应关注是否存在独立结节,该征象提示较差的RFS和OS。
- pIMA的RFS与临床T4期肺癌相当,显著差于临床T3期,将其定为临床T3期是否合理需结合预后判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare pneumonic-type invasive mucinous adenocarcinoma (pIMA) confined to a single lobe with clinical T2, T3, and T4 stage lung cancer without pathological node metastasis regarding survival after curative surgery and to identify prognostic factors for pIMA.
MATERIALS AND METHODS: From January 2010 to December 2017, 41 patients (15 male; mean age ± standard deviation, 66.0 ± 9.9 years) who had pIMA confined to a single lobe on computed tomography (CT) and underwent curative surgery were identified in two tertiary hospitals. Three hundred and thirteen patients (222 male; 66.3 ± 9.4 years) who had non-small cell lung cancer (NSCLC) without pathological node metastasis and underwent curative surgery in one participating institution formed a reference group. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Cox proportional hazard regression analysis was performed to identify factors associated with the survival of patients with pIMA.
RESULTS: The 5-year RFS and OS rates in patients with pIMA were 33.1% and 56.0%, respectively, compared with 74.3% and 91%, 64.3% and 71.8%, and 46.9% and 49.5% for patients with clinical stage T2, T3, and T4 NSCLC in the reference group, respectively. The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 NSCLC and significantly worse than that of patients with clinical stage T3 NSCLC (p = 0.012). The differences in OS between patients with pIMA and those with clinical stage T3 or T4 NSCLC were not significant (p = 0.11 and p = 0.37, respectively). In patients with pIMA, the presence of separate nodules was a significant factor associated with poor RFS and OS {unadjusted hazard ratio (HR), 4.66 (95% confidence interval [CI], 1.95-11.11), p < 0.001 for RFS; adjusted HR, 4.53 (95% CI, 1.59-12.89), p = 0.005 for OS}.
CONCLUSION: The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 lung cancer. Separate nodules on CT were associated with poor RFS and OS in patients with pIMA.
引用
- Kim W, Lee SM, Lee JB, et al. Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3? Korean J Radiol. 2022. PMID: 35213098. doi:10.3348/kjr.2021.0465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。